| Literature DB >> 31576266 |
Murat Ucar1, Alkim T Varol2, Kemal H Gülkesen3, Ahmet E Caylan2, Ömer Kutlu2, Erol Güntekin2.
Abstract
Introduction Nowadays, the expectations for functional prostatectomy outcomes are quite high. Robot-assisted laparoscopic radical prostatectomy (RALRP) has become an increasingly common treatment option for men with localized prostate cancer. In this study, we aimed to present the results of our bilateral nerve-sparing RALRP procedure and to evaluate the effects of the learning curve (LC) on perioperative data, early oncologic, and functional outcomes. Methods The records of 132 RALRP cases performed between January 2016 and March 2019 by a single surgeon experienced in open and laparoscopic radical prostatectomy were evaluated retrospectively. Results of 91 cases with the bilateral nerve-sparing technique were analyzed. The learning curve was determined using the moving average method. LC analysis using the moving average method showed that the LC stabilized between cases 40 and 50. So, patients were divided into two groups: group 1 consisted of the first 45 cases, while group 2 consisted of 46-91st cases. The groups were compared in terms of surgical, functional, and oncologic outcomes. Results The mean duration of surgery was significantly reduced in the second group (250 vs 235 min, p <0.002). However, there was no statistically significant difference between the groups in terms of hemoglobin decrease, hospitalization and catheterization time, and intraoperative and postoperative complication rates. The rates of pT2 cancers' positive surgical margins (PSMs) were 32.4% and 19.4%, respectively. The recovery rate of continence in all the patients was 90.1% at 12 months. The potency ratios were calculated as 33.8% at 12 months. There was no statistically significant difference between the groups in terms of potency and continence rates at 3 months and 12 months, postoperatively. Conclusion For surgeons experienced in retropubic radical prostatectomy (RRP) and laparoscopic radical prostatectomy (LRP) surgeries, RALRP is a safe and feasible surgical procedure for both oncological and functional outcomes even during the learning curve.Entities:
Keywords: da vinci robotic surgical system; potency; prostate cancer; robot-assisted prostatectomy; urinary continence
Year: 2019 PMID: 31576266 PMCID: PMC6764620 DOI: 10.7759/cureus.5274
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Preoperative demographic characteristics
| Group 1 (1-45) | Group 2 (46-91) | p | ||
| Age, mean±SD | 63.9±5.6 | 63.1±7.0 | 0.526 | |
| PSA, median (25th-75th percentile) | 6.0 (4.7-8.0) | 6.6 (4.9-9.4) | 0.205 | |
| Biopsy Gleason score, n (%) | 6 | 36 (80.0) | 30 (65.2) | 0.114 |
| 7-8 | 9 (20.0) | 16 (34.8) | ||
| D’amico Risk group, n (%) | Low | 30 (66.7) | 22 (51.2) | 0.309 |
| Intermediate | 9 (20.0) | 14 (32.6) | ||
| High | 6 (13.3) | 7 (16.3) | ||
Figure 1Time taken to perform robot-assisted laparoscopic radical prostatectomy (RALRP) in each case. Moving average curve of RALRP.
Perioperative and postoperative data
| Group 1 (1-45) | Group 2 (46-91) | p | |
| Operation time, median (25th-75th percentile) | 250 (227.5-270) | 235 (225-241.3) | 0.002 |
| Duration of hospitalisation, median (25th-75th percentile) | 8.0 (7.0-8.0) | 8.0 (7.8-8.0) | 0.674 |
| Duration of cathateterization, median (25th-75th percentile) | 7.0 (7.0-7.0) | 7.0 (7.0-7.0) | |
| Hemoglobin decrease, median (25th-75th percentile) | 1.9 (1.2-2.4) | 2.1 (1.0-2.5) | 0.631 |
| Postoperative RBC Transfusions (%) | 3 (6.6) | 3 (6.5) | 0.334 |
| Mean Follow-up (months) | 23.0 (20.5-29.0) | 20.0 (16.0-22.0) | <0.001 |
Comparison of clinical and pathological outcomes
| Group 1 (1-45) | Group 2 (46-91) | p | ||
| Surgical margin status, n (%) | Negative | 29 (64.4) | 34 (73.9) | 0.328 |
| Positive | 16 (35.6) | 12 (26.1) | ||
| Surgical margin status, n (%) in pT2 | Negative | 25 (67.5) | 29 (80.5) | 0.206 |
| Positive | 12 (32.4) | 7 (19.4) | ||
| Extracapsular invasion, n (%) | Yes | 8 (17.8) | 9 (19.6) | 0.827 |
| No | 37 (82.2) | 37 (80.4) | ||
| Lymphovascular invasion, n (%) | Yes | 0 (0.0) | 0 (0.0) | - |
| No | 45 (100.0) | 46 (100.0) | ||
| Perineural invasion, n (%) | Yes | 37 (82.2) | 41 (89.1) | 0.346 |
| No | 8 (17.8) | 5 (10.9) | ||
| Seminal vesicle invasion, n (%) | Yes | 3 (6.7) | 4 (10,9) | 0.479 |
| No | 5 (10.9) | 41 (89.1) | ||
| Pathological Gleason score, n (%) | 6 | 37 (82.2) | 29 (63.0) | 0.040 |
| 7-8 | 8 (17.8) | 17 (37.0) | ||
| Lymph node positive, n (%) | Yes | 0 (0.0) | 0 (0.0) | - |
| No | 45 (100.0) | 46 (100.0) | ||
| Pathological stage, n (%) | T2 | 37 (82.2) | 36 (78.3) | 0.635 |
| Biochemical recurrence | Yes | 0 | 0 | |
| No | 34 | 29 |
Functional outcomes
| Group 1; n (%) | Group 2; n (%) | p | |
| Continence | |||
| 3 months | 15/38 (39.5%) | 13/33 (39.4) | 0.995 |
| 12 months | 35/38 (92.1%) | 29/33 (87.9%) | 0.697 |
| Potency | |||
| 3 months | 2/38 (5.3%) | 2/33 (6.1%) | >0.999 |
| 12 months | 15/38 (39.5%) | 9/33 (27.3%) | 0.278 |
Surgical complications stratified by the modified Clavien Classification System
| Clavien system | Complications | Group 1 | Group 2 | Management |
| Overall | 8 | 7 | ||
| I | Urinary retention | 1 | Prolonged catheter duration | |
| I | Anastomosis site leakage | 2 | 2 | Prolonged catheter duration |
| II | Hb decline | 3 | 3 | Blood transfusion |
| IIIa | Subileus | 1 | Medical treatment | |
| IIIb | Ureteral stricture | 1 | Internal urethrotomy | |
| IIIb | Bladder perforation | 1 | Primer bladder repair | |
| IVa | PTE | 1 | Medical treatment | |
| PTE: Pulmonary thromboembolism | ||||